Drug Profile
Risankizumab - AbbVie/Boehringer Ingelheim
Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZILatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer AbbVie; Boehringer Ingelheim
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Registered Erythrodermic psoriasis; Generalised pustular psoriasis
- Preregistration Ulcerative colitis
- Phase III Palmoplantar pustulosis
- Phase II Atopic dermatitis; Hidradenitis suppurativa
- No development reported Unspecified
- Discontinued Ankylosing spondylitis; Asthma
Most Recent Events
- 01 Apr 2024 Launched for Crohn's disease (In adolescents, In the elderly, In adults) in Canada (SC)
- 01 Apr 2024 Launched for Plaque psoriasis in Australia (SC)
- 16 Jan 2024 Phase-III clinical trials in Psoriatic arthritis (In children, In adolescents, Treatment-experienced) in USA (SC) (NCT06100744) (EudraCT20235060263600)